Lymphangiogenesis in tumors: What do we know?

Microscopy Research and Technique

Volumn 60, Issue 2, 2003, Pages 171-180

  Reis Filho, Jorge Sergio ^a,b   Schmitt, Fernando C ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c University of Porto   (Portugal)

Author keywords

Lymphangiogenesis; Lymphatic vessels; Lyve 1; Podoplanin; Prox; VEGFR 3

Indexed keywords

ENDOTHELIAL CELLS;

ANIMAL MODEL; ENDOTHELIAL CELL MARKERS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; LYVE-1; PODOPLANIN; PROGNOSTIC FACTORS; PROX; VEGFR-3;

TUMORS;

ANGIOGENIC FACTOR; CD31 ANTIGEN; CD34 ANTIGEN; DESMOPLAKIN; LYVE 1 PROTEIN; PODOPLANIN; PROTEOGLYCAN; PROX 1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3; VON WILLEBRAND FACTOR;

ANGIOGENESIS; BLOOD VESSEL; HUMAN; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANIMALIA;

EID: 0037302784     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.10255     Document Type: Review

References (149)

1. Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y, Sugimachi K. 2000. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 83:887-891.
2. Andre T, Kotelevets L, Vaillant JC, Coudray AM, Weber L, Prevot S, Parc R, Gespach C, Chastre E. 2000. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 86:174-181.
3. Aprelikova O, Pajusola K, Partanen J, Armstrong E, Alitalo R, Bailey SK, McMahon JJ, Huebner K, Alitalo K. 1992. FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res 52:746-748.
4. Aukland K, Reed RK. 1993. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Ver 73:1-78.
5. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG. 1999. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 144:789-801.
6. Baxter LT, Jain RK. 1990. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res 40:246-263.
7. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Kowalski H, Oberhuber G. 2000. Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis. Anticancer Res 20:2981-2985.
8. Birner P, Schindl M, Obermair A, Breitenecker G, Kowalski H, Oberhuber G. 2001a. Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. Int J Cancer 95:29-33.
9. Birner P, Obermair A, Schindl M, Kowalski H, Breitenecker G, Oberhuber G. 2001b. Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res 7:93-97.
10. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, Kerjaschki D. 1997. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 151:1141-1152.
11. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D. 1999a. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385-394.
12. Breiteneder-Geleff S, Soleiman A, Horvat R, Amann G, Kowalski H, Kerjaschki D. 1999b. Podoplanin: a specific marker for lymphatic endothelium expressed in angiosarcoma. Verb Dtsch Ges Pathol 83:270-275.
13. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I. 1999. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967-1976.
14. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson-Welsh L, Alitalo K. 1998. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 95:14389-14394.
15. Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature 407:249-257.
16. Carreira CM, Nasser SM, di Tomaso E, Padera TP, Boucher Y, Tomarev SI, Jain RK. 2001. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 61:8079-8084.
17. Clarijs R, Ruiter DJ, Waal RMW. 2001a. Lymphangiogenesis in malignant tumors: does it occur? J Pathol 193:143-146.
18. Clarijs R, Schalkwijk L, Ruiter DJ, de Waal RM. 2001b. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma. Invest Ophthalmol Vis Sci 42:1422-1428.
19. Clauss M. 2000. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost 26:561-569.
20. Cunnick GH, Jiang WG, Gomez KF, Mansel RE. 2001. Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model. Biochem Biophys Res Commun 288:1043-1046.
21. Cursiefen C, Schlotzer-Schrehardt U, Breiteneder-Geleff S, Holbach LM. 2001. Orbital lymphangioma with positive immunohistochemistry of lymphatic endothelial markers (vascular endothelial growth factor receptor 3 and podoplanin). Graefes Arch Clin Exp Ophthalmol 239:628-632.
22. de Waal RM, van Altena MC, Erhard H, Weidle UH, Nooijen PT, Ruiter DJ. 1997. Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination. Am J Pathol 150:1951-1957.
23. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. 2000. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6:1900-1908.
24. Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, Jackson DG, Yla-Herttuala S, Alitalo K. 2001. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res 88:623-629.
25. Fabian G. 1991. On the way to understanding the lymphatic system. Z Lymphol 15:33-37.
26. Fellmer PT, Sato K, Tanaka R, Okamoto T, Kato Y, Kobayashi M, Shibuya M, Obara T. 1999. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery 126:1056-1061
27. Folkman J. 1992. The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71.
28. Folkman J. 1996. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A:2534-2539.
29. Folpe AL, Veikkola T, Valtola R, Weiss SW. 2000. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol 2000;13:180-185.
30. Fontaine R. 1977. Lymphology from the early 17th century to the beginning of the 20th century. First part: Aseli to Pecquet. Ann Chir 31:91-99.
31. Fox SB. 1997. Tumour angiogenesis and prognosis. Histopathology 30:294-301.
32. Galland F, Karamysheva A, Mattei M-G, Rosnet O, Marchetto S, Birnbaum D. 1992. Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene. Genomics 13:475-478.
33. Garlanda C, Dejana E. 1997. Heterogeneity of endothelial cells: specific markers. Arterioscler Thromb Vasc Biol 17:1193-1202
34. George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, Swift RI. 2001. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 3:420-427.
35. Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, Fox SB. 2000. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin Cancer Res 6:4278-4286.
36. Gunningham SP, Currie MJ, Han C, Turner K, Scott PA, Robinson BA, Harris AL, Fox SB. 2001. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 61:3206-3211.
37. Hamada K, Oike Y, Takakura N, Ito Y, Jussila L, Dumont DJ, Alitalo K, Suda T. 2000. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood 96:3793-3800.
38. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
39. Hashimoto I, Kodama J, Seki N, Hongo A, Yoshinouchi M, Okuda H, Kudo T. 2001. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br J Cancer 85:93-97.
40. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. 2001. Expression of vascular endothelial growth factors (VEGFA/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 80:181-188.
41. Hughes D. 2001. Alternative splicing of the human VEGFGR-3/FLT4 gene as a consequence of an integrated human endogenous retrovirus. J Mol Evol 53:77-79.
42. Ichikura T, Tomimatsu S, Ohkura E, Mochizuki H. 2001. Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol 78:132-137.
43. Jackson DG, Prevo R, Clasper S, Banerji S. 2001. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 22:317-321.
44. Jain RK. 1987. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6:559-593.
45. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K. 1997. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423-1425.
46. Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Turley H, Valtola R, Bicknell R, Harris AL. 2000. Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis. BJU Int 86:80-86.
47. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290-298.
48. Kabashima A, Maehara Y, Kakeji Y, Sugimachi K. 2001. Overexpression of vascular endothelial growth factor C is related to lymphogenous metastasis in early gastric carcinoma. Oncology 60:146-150.
49. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K. 1995. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92:3566-3570.
50. Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, Oda M, Sasaki T, Watanabe G. 2001. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 85:255-260.
51. Kanter MA. 1987. The lymphatic system: an historical perspective. Plast Reconstr Surg 79:131-139.
52. Karkkainen MJ, Petrova TV. 2000. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19:5598-5605.
53. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. 2000. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 25:153-159.
54. Karkkainen MJ, Jussila L, Ferrell RE, Finegold DN, Alitalo K. 2001a. Molecular regulation of lymphangiogenesis and targets for tissue oedema. Trends Mol Med 7:18-22.
55. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, Yla-Herttuala S, Finegold DN, Ferrell RE, Alitalo K. 2001b. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 98:12677-12682.
56. Karkkainen MJ, Mäkinen T, Alitalo K. 2002. Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol 4:E2-E5.
57. Karpanen T, Alitalo K. 2001. Lymphatic vessels as targets of tumor therapy? J Exp Med 194:F37-42.
58. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61:1786-1790.
59. Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K. 2001. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 66:159-164.
60. Kitadai Y, Amioka T, Haruma K, Tanaka S, Yoshihara M, Sumii K, Matsutani N, Yasui W, Chayama K. 2001. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 93:662-666.
61. Knudson CB, Knudson W. 1993. Hyaluronan-binding proteins in development, tissue homeostasis and disease. FASEB J 7:1233-1241.
62. Komuro H, Kaneko S, Kaneko M, Nakanishi Y. 2001. Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 127:739-743.
63. Kubo H, Fujiwara T, Jussila L, Hashi H, Ogawa M, Shimizu K, Awane M, Sakai Y, Takabayashi A, Alitalo K, Yamaoka Y, Nishikawa SI. 2000. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 96:546-553.
64. Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K. 1996. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122:3829-3837.
65. Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S, Sonoo H. 1999. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 90:977-981.
66. Leak LV. 1976. The structure of lymphatic capillaries in lymph formation. Fed Proc 35:1863-1871.
67. Leak LV, Burke JF. 1968. Ultrastructural studies on the lymphatic anchoring filaments. J Cell Biol 36:129-149.
68. Lee JY, Spicer AP. 2000. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 12:581-586.
69. Leeds SE. 1977. Three centuries of history of the lymphatic system. Surg Gynecol Obstet 144:927-934.
70. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. 2000. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 60:4324-4327.
71. Lymboussaki A, Partanen TA, Olofsson B, Thomas-Crusells J, Fletcher CD, de Waal RM, Kaipainen A, Alitalo K. 1998. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol 153:395-403.
72. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, YlaHerttuala S, Alitalo K. 2001a. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 7:199-205.
73. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, Alitalo K. 2001b. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20:4762-4773.
74. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS. 2001. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20:672-682.
75. Marchetti C. 1996. Weibel-Palade bodies and lymphatic endothelium: observations in the lymphatic vessels of normal and inflamed human dental pulps. Vasa 25:337-340.
76. Marinho A, Soares R, Ferro J, Lacerda M, Schmitt FC. 1997. Angiogenesis in breast cancer is related to age but not to other prognostic parameters. Pathol Res Pract 193:267-273.
77. Matsui K, Breitender-Geleff S, Soleiman A, Kowalski H, Kerjaschki D. 1999. Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. Nephrol Dial Transplant. 14(Suppl 1):9-11.
78. McKee CM, Penno MB, Cowman M, Burdick MD, Strieter RM, Bao C, Noble PW. 1996. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 98:2403-2413.
79. Mehes G, Witt A, Kubista E, Ambros PF. 2001. Circulating breast cancer cells are frequently apoptotic. Am J Pathol 159:17-20.
80. Nathanson SD, Zarbo RJ, Wachna DL, Spence CA, Andrzejewski TA, Abrams J. 2000. Microvessels that predict axillary lymph node metastases in patients with breast cancer. Arch Surg 135:586-593.
81. Naumov GN, MacDonald IC, Chambers AF, Groom AC. 2001. Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol 11:271-276.
82. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. 2000. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 6:2431-2439.
83. Niki T, Iba S, Yamada T, Matsuno Y, Enholm B, Hirohashi S. 2001. Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma. J Pathol 193:450-457.
84. Noble PW, McKee CM, Cowman M, Shin HS. 1996. Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J Exp Med 183:2373-2378.
85. O-charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles SA. 2000. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 18:155-161.
86. O-charoenrat P, Rhys-Evans P, Eccles SA. 2001. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92:556-568.
87. Oh SJ, Jeltsch MM, Birkenhager R, McCarthy JE, Weich HA, Christ B, Alitalo K, Wilting J. 1997. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 188:96-109.
88. Ohhashi T. 2001. Lymphodynamic factors governing lymphatic spread of carcinoma cells. Nippon Geka Gakkai Zasshi 102:435-439.
89. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, Watanabe Y, Pass HI. 1999. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81:54-61.
90. Ohta Y, Nozawa H, Tanaka Y, Oda M, Watanabe Y. 2000. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 119:804-813.
91. Olofsson B, Jeltsch M, Eriksson U, Alitalo K. 1999. Current biology of VEGF-B and VEGF-C. Curr Opin Biotechnol 10:528-535
92. Paavonen K, Horelli-Kuitunen N, Chilov D, Kukk E, Pennanen S, Kallioniemi OP, Pajusola K, Olofsson B, Eriksson U, Joukov V, Palotie A, Alitalo K. 1996. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation 93:1079-1082.
93. Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K. 2000. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156:1499-1504.
94. Papoutsi M, Tomarev SI, Eichmann A, Prols F, Christ B, Wilting J. 2001. Endogenous origin of the lymphatics in the avian chorioallantoic membrane. Dev Dyn 222:238-251.
95. Partanen TA, Alitalo K, Miettinen M. 1999. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 86:2406-2412.
96. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K. 2000. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 14:2087-2096.
97. Partanen TA, Paavonen K. 2001. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech 55:108-21.
98. Pepper MS. 2001. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 7:462-468.
99. Plate K. 2001. From angiogenesis to lymphangiogenesis. Nat Med 7:151-152.
100. Prevo R, Banerji S, Ferguson DJ, Clasper S, Jackson DG. 2001. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 276:19420-19430.
101. Rand JH, Gordon RE, Sussman II, Chu SV, Solomon V. 1982. Electron microscopic localization of factor-VIII-related antigen in adult human blood vessels. Blood 60:627-634.
102. Rishi AK, Joyce-Brady M, Fisher J, Dobbs LG, Floros J, VanderSpek J, Brody JS, Williams MC. 1995. Cloning, characterization, and development expression of a rat lung alveolar type I cell gene in embryonic endodermal and neural derivatives. Dev Biol 167:294-306.
103. Ruiter DJ, Bröcker EB. 1993. Immunohistochemistry in the evaluation of melanocytic tumors. Semin Diagn Pathol 10:76-91.
104. Ruiter DJ, Schlingemann RO, Rietveld FJ, de Waal RM. 1989. Monoclonal antibody-defined human endothelial antigens as vascular markers. J Invest Dermatol 93:25S-32S.
105. Ruiter DJ, Schlingemann RO, Westphal JR, Denijn M, Rietveld FJ, De Waal RM. 1993. Angiogenesis in wound healing and tumor metastasis. Behring Inst Mitt 92:258-272.
106. Sacchi G, Weber E, Agliano M, Cavina N, Comparini L. 1999. Lymphatic vessels of the human heart: precollectors and collecting vessels. A morpho-structural study. J Submicrosc Cytol Pathol 31:515-525.
107. Salven P, Lymboussaki A, Heikkila P, Jaaskela-Saari H, Enholm B, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H. 1998. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153:103-108.
108. Sauter B, Foedinger D, Sterniczky B, Wolff K, Rappersberger K. 1998. Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem 46:165-176.
109. Schlingemann RO, Rietveld FJ, de Waal RM, Ferrone S, Ruiter DJ. 1990. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 136:1393-1405.
110. Schlingemann RO, Rietveld FJ, Kwaspen F, van de Kerkhof PC, de Waal RM, Ruiter DJ. 1991. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol 138:1335-1347.
111. Schoppmann SF, Birner P, Studer P, Breiteneder-Geleff S. 2001. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 21:2351-2355.
112. Sinzelle E, Van Huyen JP, Breiteneder-Geleff S, Braunberger E, Deloche A, Kerjaschki D, Bruneval P. 2000. Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. Histopathology 37:93-94.
113. Skandalakis JE. 1995. I wish I had been there: highlights in the history of lymphatics. Am Surg 61:799-808.
114. Skobe M, Brown LF, Tognazzi K, Ganju RK, Dezube BJ, Alitalo K, Detmar M. 1999. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol 113:1047-1053.
115. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. 2001a. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192-198.
116. Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K, Detmar M. 2001b. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 159:893-903.
117. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. 2001c. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192-198.
118. Sleeman JP. 2000. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res 157:55-81.
119. Sleeman JP, Krishnan J, Kirkin V, Baumann P. 2001. Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech 55:61-69.
120. Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. 2001. Malignant melanoma. Arch Pathol Lab Med 125:1295-1306.
121. Sokolowska-Pituchowa J. 1969. History of studies on the lymphatic system. Folia Morphol (Warsz) 28:161-171.
122. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. 2001. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7:186-191.
123. Swartz MA. 2001. The physiology of the lymphatic system. Adv Drug Deliv Rev 50:3-20.
124. Swartz MA, Skobe M. 2001. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech 55:92-99.
125. Taipale J, Makinen T, Arighi E, Kukk E, Karkkainen M, Alitalo K. 1999. Vascular endothelial growth factor receptor-3. Curr Top Microbiol Immunol 237:85-96.
126. Tang RF, Itakura J, Aikawa T, Matsuda K, Fujii H, Korc M, Matsumoto Y. 2001. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas 22:285-292.
127. Tanigawa N, Kanazawa T, Satomura K, Hikasa Y, Hashida M, Muranishi S, Sezaki H. 1981. Experimental study on lymphatic vascular changes in the development of cancer. Lymphology 14:149-154.
128. Tischendorf F. 1978. The lymphatic system and its history. Biochem Exp Biol 14:86-97.
129. Tomarev SI, Zinovieva RD, Chang B, Hawes NL. 1998. Characterization of the mouse Prox1 gene. Biochem Biophys Res Commun 248:684-689.
130. Tsurusaki T, Kanda S, Sakai H, Kanetake H, Saito Y, Alitalo K, Koji T. 1999. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 80:309-313.
131. Ueda M, Terai Y, Kumagai K, Ueki K, Yamaguchi H, Akise D, Ueki M. 2001. Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. Gynecol Oncol 82:162-166.
132. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K. 1999. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154:1381-1390.
133. Van Trappen PO, Pepper MS. 2001. Lymphangiogenesis and lymph node microdissemination. Gynecol Oncol 82:1-3.
134. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. 2001. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20:1223-1231.
135. Warhol MJ, Sweet JM. 1984. The ultrastructural localization of von Willebrand factor in endothelial cells. Am J Pathol 117:310-315.
136. Weaver DL. 2001. Sentinel lymph node biopsy in breast cancer: creating controversy and defining new standards. Adv Anat Pathol 8:65-73.
137. Weidner N. 1993. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 10:302-313.
138. Weidner N. 1998. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 184:119-122.
139. Weidner N, Semple JP, Welch WR, Folkman J. 1991. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324:1-8.
140. Weiss L. 2000. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Ver 19:I-XI, 193-383.
141. Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M, Pammer J, Sturzl M, Kerjaschki D, Alitalo K, Tschachler E. 1999. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 79:243-251.
142. Wetterwald A, Hoffstetter W, Cecchini MG, Lanske B, Wagner C, Fleisch H, Atkinson M. 1996. Characterization and cloning of the Ell antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 18:135-132.
143. Wigle JT, Oliver G. 1999. Prox1 function is required for the development of the murine lymphatic system. Cell 98:769-778.
144. Witmer AN, van Blijswijk BC, Dai J, Hofman P, Partanen TA, Vrensen GF, Schlingemann RO. 2001. VEGFR-3 in adult angiogenesis. J Pathol 195:490-497.
145. Witte MH, Way DL, Witte CL, Bernas M. 1997. Lymphangiogenesis: mechanisms, significance and clinical implications. EXS 79:65-112.
146. Yanai Y, Furuhata T, Kimura Y, Yamaguchi K, Yasoshima T, Mitaka T, Mochizuki Y, Hirata K. 2001. Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice. J Exp Clin Cancer Res 20:419-428.
147. Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, Taniguchi K, Miwa K, Ohoyama S, Sugiyama K, Sasaki T. 1999. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 5:1823-1829.
148. Yonemura Y, Fushida S, Bando E, Kinoshita K, Miwa K, Endo Y, Sugiyama K, Partanen T, Yamamoto H, Sasaki T. 2001. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 37:918-923.
149. Zinovieva RD, Duncan MK, Johnson TR, Torres R, Polymeropoulos MH, Tomarev SI. 1996. Structure and chromosomal localization of the human homeobox gene Prox 1. Genomics 35:517-522.